USPTO Patent Grants - Peptides (C07K)

USPTO Patent Grant for Tumor Diagnosis and Treatment

The USPTO has granted patent US12583937B2 to Genentech, Inc. for compositions and methods related to the diagnosis and treatment of tumors in mammals. The patent, filed on March 16, 2022, includes 6 claims.

USPTO Grants Patent for Anti-CD73 Antibody and Use

The United States Patent and Trademark Office (USPTO) has granted patent US12583933B2 to BIOTHEUS INC. for an anti-CD73 antibody and its use in enhancing immune response and treating tumors. The patent was filed on August 28, 2020, and is effective March 24, 2026.

USPTO Patent Granted for Anti-Pro/Latent Myostatin Antibodies

The USPTO has granted a patent (US12582712B2) to Scholar Rock, Inc. for a method of making anti-pro/latent myostatin antibodies. The patent covers antibodies that specifically bind proMyostatin and/or latent Myostatin and their uses.

USPTO Patent Grant: RAS Oncoprotein Inhibitors

The USPTO has granted patent US12582660B2 to the University of Louisville Research Foundation, Inc. for inhibitors of the RAS oncoprotein, methods of making, and methods of use thereof. The patent covers compounds useful in treating diseases associated with activating mutations in RAS, particularly cancer.

Amgen Inc. Patent for KRAS G12C Inhibitor Cancer Therapy

The USPTO has granted Amgen Inc. a patent (US12582657B2) for a combination therapy involving a KRAS G12C inhibitor and other agents for treating cancers. The patent covers pharmaceutical compositions and methods of treatment.

Mutant Myocilin Disease Model Patent Granted

The USPTO has granted Regeneron Pharmaceuticals, Inc. a patent (US12582104B2) for a mutant myocilin disease model. This patent covers non-human animal models engineered to express human myocilin, intended for assessing therapeutic reagents for glaucoma.

USPTO Patent US12583917B2: IL17A Antibodies for Veterinary Use

The USPTO has granted patent US12583917B2 to Elanco US Inc. for IL17A antibodies and antagonists intended for treating conditions in animals, including companion animals. The patent details specific antibody embodiments and IgG Fc variant polypeptides designed to reduce immune responses.

USPTO Patent Grant: Modified Plasma Clotting Factor VIII

The USPTO has granted patent US12583907B2 to AAVnerGene, INC. for modified human factor VIII polypeptides with enhanced activity. These polypeptides and their encoding viral vectors are intended for treating FVIII deficiencies, such as hemophilia A.

USPTO Patent Grant: DNA-binding domain transactivators

The USPTO has granted a patent (US12583902B2) to the University of Massachusetts for DNA-binding domain transactivators and their uses. The patent covers recombinant adeno-associated viruses (rAAVs) designed to modify target gene expression in cells.

USPTO Patent Grant for Caged-Degron Molecular Feedback Circuits

The USPTO has granted patent US12583896B2 to The Regents of the University of California for caged-degron-based molecular feedback circuits. The patent covers methods of modulating signaling pathways in cells using these circuits, with a filing date of January 6, 2020.

USPTO Patent Grant for LRP6 Protein Binding Antibodies

The USPTO has granted a patent (US12583919B2) to Antlera Therapeutics Inc. for antibodies that specifically bind to LRP6 proteins and methods of their use. The patent was filed on August 14, 2020, and is set to be granted on March 24, 2026.

USPTO Patent Grant for Cancer Diagnosis using Anti-BAG2 Antibody

The USPTO has granted a patent (US12583915B2) to Medpacto, Inc. for methods of diagnosing cancer using an anti-BAG2 antibody. The patent covers compositions comprising antibodies that specifically bind to BAG2 polypeptides or fragments thereof.

USPTO Patent Grant: Antibody Inhibitors for Staphylococcus Aureus Treatment

The USPTO has granted patent US12583913B2 for antibody inhibitors targeting Staphylococcus aureus, specifically coagulases SC and vWbp. This patent covers therapeutic methods and detection techniques utilizing these monoclonal antibodies.

USPTO Patent Grant for T Cell Antigen Receptor Complex

The USPTO has granted patent US12583910B2 to Tsinghua University for a T cell antigen receptor complex and its preparation method. This patent covers antibodies, T cell receptors, and immune cells designed to recognize pMHC complexes and activate T cells for therapeutic use.

Microsoft Technology Licensing, LLC Awarded Patent for Anti-lock Hinged Device

The USPTO has granted Microsoft Technology Licensing, LLC a patent for an anti-lock hinged device. The patent, US12577979B2, describes a mechanism designed to prevent over-extension in hinged devices. The filing date for this patent application was October 23, 2023.

USPTO Grants Patent for Single Molecule Peptide Sequencing

The USPTO has granted a patent (US12578345B2) to The University of Texas System for methods of single molecule peptide sequencing. The patent covers techniques for identifying polypeptide sequences within a mixture by immobilizing, labeling, and analyzing the polypeptide.

USPTO Patent for Alzheimer's Detection Kits

The USPTO has granted a patent (US12578344B2) to NEUROQUEST LTD. for compositions, kits, and methods for detecting preclinical Alzheimer's Disease. The patent covers binding agents for biomarkers such as CD163 and scavenger receptors, and methods for diagnosing AD and assessing therapeutic efficacy.

USPTO Patent Grant: Canine TK1 Protein Determination Kit

The USPTO has granted patent US12578340B2 to ALERTIX VETERINARY DIAGNOSTICS AB for a kit to determine canine TK1 protein levels. The kit utilizes specific monoclonal antibodies to detect peptides from canine TK1.

USPTO Patent Grant for Polypeptide Reagent Kit

The USPTO has granted a patent (US12578329B2) to Shimadzu Corporation for a reagent kit containing polypeptides designed for detecting intermolecular interactions. The patent details specific amino acid sequences and their modifications for use in this kit.